Maduck Sean's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed Apr 2, 2025
- Accession no.
- 0000950170-25-049816
- Filed
- Apr 2, 2025
- Trade date
- Mar 31-Apr 1, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 2 derivative transactions. Open-market sales total $10.1M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maduck SeanCIK 0001698310 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 31, 2025 | Common Stock | MOption exerciseAcquired | +100,000 | $8.27 | +$827,000 | 185,622 | Direct | |
| Mar 31, 2025 | Common Stock | SSaleDisposed | −79,277 | $100.26F3 | −$7,948,312.02 | 106,345 | Direct | |
| Mar 31, 2025 | Common Stock | SSaleDisposed | −15,133 | $101.43F4 | −$1,534,940.19 | 91,212 | Direct | |
| Mar 31, 2025 | Common Stock | SSaleDisposed | −5,590 | $102.16F5 | −$571,074.4 | 85,622 | Direct | |
| Apr 1, 2025 | Common Stock | MOption exerciseAcquired | +590 | $5.05 | +$2,979.5 | 86,212 | Direct | |
| Apr 1, 2025 | Common Stock | SSaleDisposed | −590 | $114.55F6 | −$67,584.5 | 85,622 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 31, 2025 | Common Stock | MOption exerciseDisposed | −100,000 | $0.00 | $0 | 300,000 | Direct | |
| Apr 1, 2025 | Common Stock | MOption exerciseDisposed | −590 | $0.00 | $0 | 121,396 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $100.00 to $100.97 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F4
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $101.00 to $101.95 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F5
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $102.00 to $102.5250 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F6
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.29 to $114.71 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.